Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) EBIT: €31.4 Mil (TTM As of Dec. 2025)


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
79 GF Score
Price €4.52
GF Value €3.50
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co EBIT?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 -2.59% 79 EBIT is €31.4 Mil as of Dec. 2025. GuruFocus rates FRA:I54 with a GF Score™ of 79/100 and a GF Value™ of €3.50 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Biocytogen Pharmaceuticals (Beijing) Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €19.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €31.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC % for the quarter that ended in Dec. 2025 was 18.24%. Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 23.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biocytogen Pharmaceuticals (Beijing) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.71%.

Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=42.988 * ( 1 - 2.5% )/( (228.42 + 231.192)/ 2 )
=41.9133/229.806
=18.24 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=300.416 - 21.451 - ( 55.084 - max(0, 56.902 - 107.447+55.084))
=228.42

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=451.585 - 72.652 - ( 189.518 - max(0, 112.801 - 260.542+189.518))
=231.192

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=39.646/( ( (163.414 + max(15.705, 0)) + (165.611 + max(-15.857, 0)) )/ 2 )
=39.646/( ( 179.119 + 165.611 )/ 2 )
=39.646/172.365
=23.00 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(24.276 + 15.355 + 10.695) - (21.451 + 0 + 13.17)
=15.705

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(36.392 + 21.189 + 11.795) - (72.652 + 0 + 12.581)
=-15.857

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biocytogen Pharmaceuticals (Beijing) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=31.36/4435.281
=0.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co EBIT Related Terms

Biocytogen Pharmaceuticals (Beijing) Co EBIT Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co EBIT Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -70.34 -73.82 -36.00 17.66 31.41

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -17.67 0.72 16.92 11.54 19.82

FRA:I54 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT falls into.


FRA:I54
79GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €31.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €31.4 Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a EBIT of €31.4 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biocytogen Pharmaceuticals (Beijing) Co.
Is Biocytogen Pharmaceuticals (Beijing) Co's EBIT too high?
Biocytogen Pharmaceuticals (Beijing) Co's current EBIT is €31.4 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's EBIT compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's EBIT of €31.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biocytogen Pharmaceuticals (Beijing) Co. Biocytogen Pharmaceuticals (Beijing) Co's current EBIT is €31.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.50, compared to a current price of €4.52 — trading 29.1% above its estimated fair value. The current EBIT is €31.4 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current EBIT is €31.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €4.52 is trading 29.1% above its estimated GF Value™ of €3.50. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Modestly Overvalued.

Key valuation signals for FRA:I54:

  • EBIT: €31.4 Mil
  • GF Value™: €3.50 vs. price of €4.52 (29.1% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score

Get the complete analysis for FRA:I54

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.52
Price
€3.50
GF Value